This is a KP.2 news story, published by CityNews, that relates primarily to COVID-19 news.
For more KP.2 news, you can click here:
more KP.2 newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from CityNews, you can click here:
more news from CityNewsOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
current vaccine. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Spikevax mRNA vaccine news, Canadian Medical Association news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Moderna vaccinesCityNews
•
79% Informative
Pfizer-BioNTech’s updated COVID-19 vaccine protects against one of the most recently circulating variants of the virus.
The mRNA vaccine, called Comirnaty , targets the KP.2 subvariant of Omicron , replacing the previous version.
VR Score
77
Informative language
75
Neutral language
60
Article tone
formal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links